Regen BioPharma Inc (OTCQB:RGBP) made waves Tuesday with news of additional small molecule inhibitors.
The San Diego-based pharmaceutical company told the media its researchers have identified three new series of small molecule drugs that inhibit NR2F6, bringing the total number of these series to five.
Said Chief Scientific Officer Harry Lander, "Finding potent small molecule inhibitors of NR2F6 is central to our goal of identifying and protecting the intellectual property landscape around this program.
"Therefore, we continue to screen for NR2F6 inhibitors using a second proprietary assay and have identified three new series of drugs that inhibit NR2F6 in a concentration-dependent manner."
A news release out early Tuesday afternoon also said the NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem-cell differentiator.
The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated.
The discovery led to a good deal of activity in the company’s shares, which hoisted six-100ths of a cent late Tuesday, or 10%, to 66-100ths of a cent, on just over 10 million shares.
